Latest news and press releases about Keros Therapeutics, Inc. (KROS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Price
| Price | $10.74 |
| Market Cap | $344M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -1.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -21.40% |
| Return on Invested Capital | -35.25% |
| Return on Assets | -28.91% |
| Gross Margin | 94.68% |
| Operating Margin | -675.82% |
| Net Margin | -553.88% |
Related companies: ABSI · CRVS · CTMX · MLTX · NAGE · OLMA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of KROS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks